Early versus periprocedural administration of abciximab for primary angioplasty: a pooled analysis of 6 studies

Jochen Gödicke, Marcus Flather, Marko Noc, Mariann Gyöngyösi, Hans-Richard Arntz, Lars Grip, Henrique Mesquita Gabriel, Kurt Huber, Fiona Nugara, Joachim Schröder, Leif Svensson, Duolao Wang, Simona Zorman, Gilles Montalescot

Research output: Contribution to journalArticlepeer-review

49 Citations (Scopus)


The 2004 ACC/AHA guidelines on ST-elevation myocardial infarction state that it is reasonable to start treatment with abciximab as early as possible before primary percutaneous coronary intervention (PCI). We investigated the potential benefit of early use of abciximab by pooling data from all the available studies.
Original languageEnglish
Pages (from-to)1015
JournalAmerican Heart Journal
Issue number5
Publication statusPublished - Nov 2005


  • Angioplasty, Balloon, Coronary
  • Antibodies, Monoclonal
  • Female
  • Humans
  • Immunoglobulin Fab Fragments
  • Male
  • Middle Aged
  • Time Factors

Cite this